Welcome to our dedicated page for Urogen Pharma SEC filings (Ticker: URGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The UroGen Pharma Ltd. (URGN) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an Israel-organized biotechnology issuer listed on The Nasdaq Stock Market, UroGen submits periodic and current reports that describe its financial condition, oncology pipeline, and corporate governance.
Investors can review Forms 10-K and 10-Q for detailed discussions of UroGen’s business, including its RTGel® reverse-thermal hydrogel platform, approved products for low-grade upper tract urothelial cancer and recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, and revenue from product sales. These reports also outline research and development spending on programs such as UGN-103, UGN-104, and UGN-501, along with risk factors specific to urothelial and specialty cancer drug development.
Form 8-K filings provide timely updates on material events, such as quarterly financial results, executive compensation decisions, FDA approvals, and key commercialization milestones like the assignment of a permanent HCPCS Level II J Code (J9282) for ZUSDURI. Proxy materials on Schedule 14A describe annual meeting agendas, board elections, equity incentive plans, and advisory votes on executive pay and auditor engagement.
On Stock Titan, these filings are paired with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand complex oncology, financial, and governance disclosures. Users can also access information relevant to insider and equity-related activity through compensation and equity plan discussions referenced in UroGen’s 8-K and DEF 14A filings.
UroGen Pharma Ltd. files its annual report describing a focused uro-oncology business built around its RTGel reverse-thermal hydrogel drug-delivery platform. The company develops therapies that keep chemotherapy and immunotherapy in the urinary tract longer, aiming to improve tumor control with minimally invasive treatments.
UroGen’s approved products are Jelmyto for low-grade upper tract urothelial carcinoma and Zusduri for recurrent low-grade intermediate-risk non–muscle invasive bladder cancer, both RTGel-based mitomycin formulations designed for chemoablation instead of repeated surgery. The report details broad payer coverage, dedicated commercial infrastructure, and ongoing registries and follow-up studies to characterize long-term outcomes.
The pipeline includes next-generation mitomycin products UGN‑103 and UGN‑104 under a medac collaboration, and UGN‑501, an oncolytic virus acquired from IconOVir to target high‑grade disease and potentially other cancers. UroGen emphasizes its intellectual property estate, regulatory pathways (including 505(b)(2), orphan exclusivity and Orange Book listings), and experience navigating FDA approval, fast-track and breakthrough processes.
UroGen Pharma reported full-year 2025 revenue of $109.8 million, up from $90.4 million in 2024, driven by the FDA approval and commercial launch of bladder cancer drug ZUSDURI and growth of kidney cancer therapy JELMYTO.
Research and development expenses rose to $67.1 million and selling, general and administrative costs increased to $155.1 million, reflecting clinical programs and launch investments. The company posted a net loss of $153.5 million, or $3.19 per share, and ended 2025 with $120.5 million in cash, cash equivalents and marketable securities.
Management highlighted 2026 as a pivotal year for the ZUSDURI rollout, with early signs of increasing physician adoption following permanent J‑Code reimbursement. UroGen guided 2026 JELMYTO net product sales to $97–$101 million and expects operating expenses of $240–$250 million while advancing late‑stage candidates UGN‑103 and UGN‑104 toward planned regulatory milestones.
UroGen Pharma Ltd. entered into a new secured term loan agreement providing up to $250,000,000 in borrowings through two tranches. A $200,000,000 Tranche A loan was funded immediately, with Tranche B of $50,000,000 available at the borrower’s election through June 30, 2027, subject to conditions.
The Tranche A proceeds refinance an existing $125,000,000 term loan and support general corporate and working capital needs; Tranche B would also fund general corporate purposes. The debt carries a fixed 8.25% annual interest rate, quarterly payments, and matures five years after the Tranche A closing date, with principal amortization beginning in the first quarter of 2030.
The facility is guaranteed by UroGen Pharma Ltd., is secured by substantially all tangible and intangible assets (including intellectual property), and includes customary affirmative and restrictive covenants but no financial covenants. Prepayments trigger a 1% exit fee and, if made within one year of each tranche’s closing, a makewhole equal to foregone interest, and a change of control requires repayment.
UroGen Pharma Ltd. director exercises RSUs into shares. On February 26, 2025, director James A. Robinson Jr. exercised 2,000 Restricted Stock Units, each representing a right to receive one ordinary share. This conversion resulted in the acquisition of 2,000 ordinary shares at a stated price of $0.00 per share.
After these transactions, his reported holdings increased to 4,000 Restricted Stock Units and 4,000 ordinary shares, all held directly. The activity reflects an equity award conversion rather than an open-market purchase or sale.
Barrett Elizabeth A. reported acquisition or exercise transactions in this Form 4 filing.
UroGen Pharma Ltd. reported that Chief Executive Officer Elizabeth A. Barrett received a grant of 153,195 restricted stock units on January 31, 2026. Each RSU represents the right to receive one ordinary share at no purchase price. One-third of the RSUs will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, aligning the CEO’s compensation with the company’s long-term performance.
The Toronto-Dominion Bank filed an amended Schedule 13G showing a passive ownership position in UroGen Pharma Ltd. as of 12/31/2025. The bank reports beneficial ownership of 2,302,334 ordinary shares, representing 4.9% of the outstanding class.
TD Bank has sole voting and dispositive power over all reported shares and no shared power. It certifies the shares were acquired and are held in the ordinary course of business, not to change or influence control of UroGen Pharma.
UroGen Pharma Ltd. General Counsel Jason Drew Smith reported equity award activity and related share sales. On January 31, 2026, multiple tranches of previously granted restricted stock units (RSUs) vested and were settled into ordinary shares, including awards originally granted in 2023, 2024, and 2025.
That same day, Smith received a new grant of 32,609 RSUs, which will vest in three equal installments on January 31, 2027, January 31, 2028, and January 31, 2029. On February 3, 2026, he sold ordinary shares at $19.69 per share to cover withholding tax obligations arising from the RSU settlements, and continued to hold tens of thousands of UroGen ordinary shares directly after these transactions.
UroGen Pharma Ltd.'s Chief Medical Officer, Mark Schoenberg, reported routine share sales linked to tax withholding on equity compensation. On February 3, 2026, he sold blocks of 1,844, 1,843, and 3,686 ordinary shares at $19.69 per share.
According to the filing, these shares were sold to satisfy withholding tax obligations arising from the settlement of restricted stock units. After these transactions, Schoenberg directly beneficially owned 144,985 ordinary shares of UroGen Pharma.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg reported equity compensation activity involving restricted stock units (RSUs) and ordinary shares. On January 31, 2026, previously granted RSUs converted into a total of 13,333 ordinary shares at an exercise price of $0, increasing his directly held ordinary shares.
On the same date, he received a new grant of 20,000 RSUs at $0. One-third of the shares underlying this new RSU award will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, providing staged future share delivery if vesting conditions are met.
UroGen Pharma Ltd. reported that its Chief Financial Officer, Chris Degnan, received a grant of restricted stock units on January 31, 2026. The award covers 32,609 RSUs, each representing a contingent right to receive one ordinary share of UroGen Pharma.
According to the grant terms, one-third of the shares underlying the RSUs will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, subject to the standard conditions. Following this grant, Degnan beneficially owns 32,609 derivative securities directly.